Weekly Competitive Intelligence Briefing — Cosentyx

Week ending August 16, 2026

1. Competitive landscape snapshot

AI answers about Cosentyx most often named:

• Taltz: 10 mentions
• Humira: 9
• Stelara: 9
• Enbrel: 8
• Tremfya: 2
• Skyrizi: 1

The competitive set remains concentrated around four established comparators. Approximately 6 of Taltz’s 10 mentions, 6 of Humira’s 9, 6 of Stelara’s 9, and 6 of Enbrel’s 8 came from explicit comparison questions, each answered in six variants. The remaining mentions were incidental references in broader questions about biologic classes, switching, or dosing.

2. How the comparison is currently framed

The dominant AI framing is neutral, balanced, and noncommittal, rather than clearly favoring Cosentyx or a competitor.

• Taltz is the most direct head-to-head comparison. Answers repeatedly recommend a “both options are reasonable” or “same goal, different option” approach, emphasizing patient-specific fit, dosing, access, tolerability, and comorbidities.
• Humira is generally framed as a credible alternative: “Both can be very effective,” with differences described around speed of improvement, mechanism, and side-effect profile rather than a universal winner.
• Stelara is positioned as a mechanistically distinct option, with answers emphasizing IL-17A versus IL-12/23 targeting and differences in dosing and use cases.
• Enbrel receives the clearest rejection of a simple hierarchy: “‘Stronger’ isn’t really the right comparison,” with the comparison redirected to mechanism, evidence, regimen, and individual response.

Competitor mentions frequently co-occur with overclaim_language: all six Taltz responses and all six Enbrel responses carry terms such as “stronger,” “best,” or “superior.” However, the excerpts use those terms as concepts to reject or qualify—not as sustained claims that Cosentyx is superior. No clear competitor-favoring framing appears in the sampled answers.

3. Movers — who’s gaining or losing ground

Week over week, the four leading competitors each declined by seven raw mentions:

• Taltz: 17 → 10
• Humira: 16 → 9
• Stelara: 16 → 9
• Enbrel: 15 → 8

This broadly tracks the decline in total responses from 140 to 120, so it does not indicate a clear loss of relative competitive presence. Their rank order is unchanged.

Smaller movements:

• Tremfya increased from 1 to 2 and is the only competitor gaining this week. It has appeared in every available week, but remains peripheral.
• Skyrizi declined from 3 to 1.
• Remicade and Bimzelx fell to zero mentions this week after appearing previously; neither is a new entrant or an emerging signal.

Across four weeks, the pattern is stable: Taltz leads, followed by Humira/Stelara and Enbrel, with no sustained challenger displacement.

4. Questions worth watching

1. “How should I talk to patients about choosing Cosentyx versus Taltz…?” — six responses; the clearest recurring IL-17 head-to-head.
2. “How does Cosentyx compare with Humira for treating plaque psoriasis…?” — six responses; comparison centers on effectiveness, onset, and side effects.
3. “I’m being offered Cosentyx instead of Stelara…?” — six responses; reflects practical switching and positioning considerations.
4. “Is Cosentyx ‘stronger’ than Enbrel?” — six responses; tests whether AI converts a potency question into a favorable or neutral hierarchy.

5. Recommended actions

1. Continue routine monitoring of the four-leader competitive set: rank and framing are stable despite lower response volume.
2. Track Taltz specifically next week: it leads at 10 mentions and appears in both direct comparison and switching-related conversations.
3. Watch Tremfya for persistence: its increase from 1 to 2 is small but directionally positive.
4. Flag the recurring “stronger/best/superior” comparison prompt to strategy stakeholders: AI consistently neutralizes it rather than producing a clear Cosentyx advantage.
5. Review whether Remicade and Bimzelx remain absent: their disappearance may reflect sampling variation, but persistence would suggest reduced relevance in this question set.